Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer
Oncocyte Corp (NASDAQ: OCX) has appointed Dr. Paul Billings as Consulting Chief Medical Officer in a part-time role. Dr. Billings, a renowned diagnostics specialist with over 40 years of experience, will support strategic and clinical goals for the company.
Dr. Billings previously served as CEO and Chairman at Biological Dynamics, focusing on exosome-based diagnostics for early cancer detection, and as Chief Medical Officer at Natera during key commercialization phases. He has held advisory and leadership positions at major companies including LabCorp, Quest Diagnostics, and Thermo Fisher Scientific.
Holding M.D. and Ph.D. degrees in immunology from Harvard University, Dr. Billings is board certified in internal medicine and medical genetics. He has held academic positions at Harvard, Stanford, and UC San Francisco, and served on Advisory Boards at the FDA and HHS.
Oncocyte Corp (NASDAQ: OCX) ha nominato Dr. Paul Billings come Chief Medical Officer Consulente in un ruolo part-time. Il Dr. Billings, un rinomato specialista in diagnostica con oltre 40 anni di esperienza, supporterà gli obiettivi strategici e clinici dell'azienda.
In precedenza, il Dr. Billings ha ricoperto il ruolo di CEO e Presidente presso Biological Dynamics, concentrandosi sulla diagnostica basata su esosomi per la rilevazione precoce del cancro, e ha lavorato come Chief Medical Officer presso Natera durante fasi chiave di commercializzazione. Ha occupato posizioni di consulenza e leadership in importanti aziende tra cui LabCorp, Quest Diagnostics e Thermo Fisher Scientific.
Con lauree in Medicina e Dottorato in immunologia presso l'Università di Harvard, il Dr. Billings è certificato in medicina interna e genetica medica. Ha ricoperto posizioni accademiche presso Harvard, Stanford e UC San Francisco, e ha servito in Comitati Consultivi presso la FDA e il HHS.
Oncocyte Corp (NASDAQ: OCX) ha nombrado al Dr. Paul Billings como Director Médico Consultor en un rol a tiempo parcial. El Dr. Billings, un renombrado especialista en diagnóstica con más de 40 años de experiencia, apoyará las metas estratégicas y clínicas de la empresa.
El Dr. Billings anteriormente se desempeñó como CEO y Presidente en Biological Dynamics, centrándose en diagnósticos basados en exosomas para la detección temprana de cáncer, y como Director Médico en Natera durante fases clave de comercialización. Ha ocupado posiciones de asesoría y liderazgo en grandes empresas, incluyendo LabCorp, Quest Diagnostics y Thermo Fisher Scientific.
Con títulos de M.D. y Ph.D. en inmunología de la Universidad de Harvard, el Dr. Billings está certificado en medicina interna y genética médica. Ha ocupado posiciones académicas en Harvard, Stanford y la UC San Francisco, y ha servido en Consejos Asesores en la FDA y el HHS.
Oncocyte Corp (NASDAQ: OCX)는 Paul Billings 박사를 파트타임 컨설팅 최고 의료 책임자로 임명했습니다. Billings 박사는 40년 이상의 경력을 가진 저명한 진단 전문가로, 회사의 전략적 및 임상 목표를 지원할 것입니다.
Billings 박사는 Biological Dynamics의 CEO 겸 회장으로 일하며 조기 암 검출을 위한 엑소좀 기반 진단에 주력하였고, Natera의 최고 의료 책임자로 중요한 상업화 단계에서 활동했습니다. LabCorp, Quest Diagnostics 및 Thermo Fisher Scientific과 같은 주요 회사에서 자문 및 리더십 역할을 맡았습니다.
하버드 대학교에서 면역학으로 M.D. 및 Ph.D. 학위를 취득한 Billings 박사는 내과 및 의학 유전학 분야에서 보드 인증을 받았습니다. 하버드, 스탠포드 및 UC 샌프란시스코에서 교수직을 역임하였고, FDA 및 HHS의 자문 위원회에서 활동했습니다.
Oncocyte Corp (NASDAQ: OCX) a nommé Dr. Paul Billings en tant que Chief Medical Officer Consultant à temps partiel. Le Dr Billings, un spécialiste renommé en diagnostic avec plus de 40 ans d'expérience, soutiendra les objectifs stratégiques et cliniques de l'entreprise.
Le Dr Billings a auparavant été PDG et Président de Biological Dynamics, se concentrant sur le diagnostic basé sur les exosomes pour la détection précoce du cancer, ainsi que Chief Medical Officer chez Natera durant les phases clés de commercialisation. Il a occupé des postes de conseil et de direction dans de grandes entreprises telles que LabCorp, Quest Diagnostics et Thermo Fisher Scientific.
Titulaire d'un M.D. et d'un Ph.D. en immunologie de l'Université de Harvard, le Dr Billings est certifié en médecine interne et en génétique médicale. Il a occupé des postes académiques à Harvard, Stanford et UC San Francisco, et a siégé aux conseils consultatifs de la FDA et du HHS.
Oncocyte Corp (NASDAQ: OCX) hat Dr. Paul Billings als beratenden Chief Medical Officer in Teilzeit ernannt. Dr. Billings, ein renommierter Diagnosetechnikspezialist mit über 40 Jahren Erfahrung, wird die strategischen und klinischen Ziele des Unternehmens unterstützen.
Dr. Billings war zuvor CEO und Vorsitzender von Biological Dynamics und konzentrierte sich auf exosom-basierte Diagnostik zur frühen Erkennung von Krebs. Außerdem war er Chefarzt bei Natera in wichtigen Phasen der Kommerzialisierung. Er hat beratende und leitende Positionen bei großen Unternehmen wie LabCorp, Quest Diagnostics und Thermo Fisher Scientific innegehabt.
Dr. Billings hat einen M.D. und einen Ph.D. in Immunologie von der Harvard University und ist in Innerer Medizin und medizinischer Genetik zertifiziert. Er war in akademischen Positionen an Harvard, Stanford und UC San Francisco tätig und Mitglied von Beratungsräten der FDA und HHS.
- Appointment of highly experienced executive with proven track record in commercializing diagnostic tests
- Strategic expertise in regulatory and reimbursement processes from previous roles
- Extensive industry network and relationships with major diagnostic companies
- Part-time consulting role rather than full-time commitment
- Potential conflict with other ongoing commitments and advisory roles
- Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine
- Will provide key regulatory and reimbursement support
- Will assist business development efforts and strategic partnerships
IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company’s Consulting Chief Medical Officer. In this part-time role, he will support a range of strategic and clinical goals for Oncocyte.
Dr. Billings is a recognized pioneer in genomics and precision medicine with over 40 years of experience spanning academia, government, and the biotechnology industry. He joins Oncocyte from Biological Dynamics, where he served as CEO and Chairman, driving innovation in exosome-based diagnostics for early cancer detection. Previously, he served as Chief Medical Officer at Natera, Inc., during the commercialization phase of its blood test for kidney transplant rejection as well as its cancer blood test that can identify minimal residual disease. He has also been an advisor or a physician leader with Laboratory Corporation of America Holdings, Quest Diagnostics, Life Technologies Corp, Johnson & Johnson, and Thermo Fisher Scientific, contributing to transformative advances in molecular medicine.
“We are thrilled to welcome Dr. Billings to the Oncocyte team,” said Josh Riggs, CEO of Oncocyte. “He is a legend in molecular diagnostics with a proven track record of not only advancing groundbreaking technologies but also bringing them to market and making a tangible impact on patient care.”
“My interest is in individualizing care – in driving clinical utility and better outcomes. Enabling hospitals and providers to do the testing nearer to the patient, with quality and favorable economics, will result in improved practice,” Dr. Billings said. “I am honored to collaborate with this talented and passionate team in bridging the gap between clinical innovation and the accessibility of care.”
Dr. Billings holds M.D. and Ph.D. degrees in immunology from Harvard University, with postgraduate training at the University of Washington. He is board certified as an internal medicine and medical genetics specialist. He has held academic positions at Harvard, Stanford, and UC San Francisco, where he has mentored the next generation of leaders in genetics and medicine. He has also served on the Advisory Boards at the Food and Drug Administration (FDA.) and the Department of Health and Human Services (HHS)
About Oncocyte
Oncocyte is a leading diagnostics technology company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
Forward-Looking Statements
Any statements that are not historical fact (including but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, Oncocyte’s commercialization efforts and progress with respect to its molecular diagnostic tests and its proprietary diagnostic technology for use in organ transplant patients, the expectation of successful commercialization and growth of the total addressable market for VitaGraft Kidney, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte’s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/88033c51-bf0c-4f09-a6a7-985c2dae531e
FAQ
What is Dr. Paul Billings' role at Oncocyte (OCX)?
What experience does Dr. Billings bring to Oncocyte (OCX)?
How will Dr. Billings' appointment impact Oncocyte's (OCX) diagnostic development?
What are Dr. Billings' academic credentials and regulatory experience for OCX?
